| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A607314-5mg |
5mg |
期货  |
| |
| A607314-25mg |
25mg |
期货 |
|
| 规格或纯度 | Moligand™ |
|---|---|
| 英文名称 | A947 |
| 作用机制 | SWI/SNF 相关；基质相关；染色质的肌动蛋白依赖性调节器；亚家族 a；成员 2;SWI/SNF 相关；基质相关；染色质的肌动蛋白依赖性调节器；亚家族 a；成员 4 |
| IIUPAC Name | (2S,4R)-1-[(2R)-2-[3-[4-[[4-[3-[4-[3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]pyridin-2-yl]oxycyclobutyl]oxypiperidin-1-yl]methyl]piperidin-1-yl]-1,2-oxazol-5-yl]-3-methylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide |
|---|---|
| INCHI | 1S/C61H76N12O7S/c1-36(2)57(61(77)72-34-45(74)26-52(72)60(76)65-37(3)40-9-11-41(12-10-40)58-38(4)64-35-81-58)54-30-55(68-80-54)70-23-16-39(17-24-70)31-69-21-18-46(19-22-69)78-47-27-48(28-47)79-56-25-42(15-20-63-56)73-43-13-14-44(73)33-71(32-43)51-29-50(66-67-59(51)62)49-7-5-6-8-53(49)75/h5-12,15,20,25,29-30,35-37,39,43-48,52,57,74-75H,13-14,16-19,21-24,26-28,31-34H2,1-4H3,(H2,62,67)(H,65,76)/t37-,43?,44?,45+,47?,48?,52-,57+/m0/s1 |
| InChi Key | QQVCUSPUMMUFTD-NCXNEFEISA-N |
| Smiles | Cc1c(scn1)c1ccc(cc1)[C@H](C)NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](c1cc(no1)N1CCC(CC1)CN1CCC(CC1)OC1CC(C1)Oc1nccc(c1)N1C2CCC1CN(C2)c1cc(nnc1N)c1ccccc1O)C(C)C)O |
| PubChem CID | 139546336 |
| 1. Cantley J, Ye X, Rousseau E, Januario T, Hamman BD, Rose CM, Cheung TK, Hinkle T, Soto L, Quinn C et al.. (2022) Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.. Nat Commun, 13 (1): (6814). [PMID:36357397] |
首页
400-620-6333
